@article{Haas_Shevach_Davis_Eisen_Gross-Gupil_Kapoor_Master_Ryan_Schimdinger_2022, title={Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma}, volume={3}, url={https://siuj.org/index.php/siuj/article/view/222}, DOI={10.48083/VSQG7437}, abstractNote={<p>Patients undergoing definitive surgery or ablative techniques for nonmetastatic kidney cancer have varying degrees<br>of risk of recurrent disease post procedure. The ultimate goal of “adjuvant therapy” is to reduce the incidence of<br>recurrent disease, and to cure more patients. We summarize the current state of perioperative therapy for kidney<br>cancer and explore future directions to develop optimal adjuvant strategies. We define risk and risk of recurrence<br>post-definitive therapy, describe the controversies surrounding the trial landscape of adjuvant vascular endothelial<br>growth factor receptor tyrosine kinase inhibitors and immune checkpoint inhibitors. We review data on neoadjuvant<br>therapy before advanced kidney cancer resection. Radiologic, ethnic, economic, and geographic considerations<br>with respect to adjuvant therapy are highlighted, as well as adjuvant therapy issues especially pertinent to patients,<br>future directions in adjuvant trial design specifically targeted to biomarkers and patient selection, and sequencing of<br>treatment after adjuvant therapy in those patients with recurrence.</p&gt;}, number={6}, journal={Société Internationale d’Urologie Journal}, author={Haas, Naomi B. and Shevach, Jeffrey and Davis, Ian D. and Eisen, Tim and Gross-Gupil, Marine and Kapoor, Anil and Master, Viraj A. and Ryan, Christopher W. and Schimdinger, Manuela}, year={2022}, month={Nov.}, pages={464-476} }